Genedrive building on impressive year of progress for its testing kits
Genedrive, the Manchester-based point of care pharmacogenetic testing company, hailed a year of ‘significant commercial and operational progress’ in a trading update for the period ended June 30, 2026, today (July 13).
The group’s Genedrive MT-RNR1 testing kit helps protect from irreversible, lifelong bilateral hearing loss, while its Genedrive CYP2C19 kit is used with stroke patients.
More than 13,000 new-born babies have been tested in clinical settings using the MT-RNR1 ID Kit to date, with in excess of 40 protected fro... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
